Clinical Trial Search

Primary: Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period — 6.1; 12.7; 6.3; 12.7 attacks — p=<0.0001

Primary: Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 — 21.6; 5.3 percentage of success — p=0.0044

Primary: Time to Beginning of Substantial Relief of the Defining Symptom — 2.0; 4.0 hours — p=0.048

Primary: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period — 167; 112 Participants

Primary: Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16 — 25; 14; 40 Participants

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Overall PD Reduction — 1.25; 0.66 mm

Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg

Primary: Change From Baseline in A1C at Week 18 — -1.00; 0.02 Percent — p=<0.001

Primary: Proportion of Participants With Clinical Remission Per Mayo Score at Week 8 — 9.2; 10.0; 18.5 Proportion of participants — p=0.031

Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Post-dose in Patients With Exercise-Induced Bronchoconstriction…

Primary: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment — -41.69; -46.83; -49.10; -7.53 percent change of…

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12 — -39.5; -54.2; -46.6; -59.1 Percent change in LDL-C — p=<0.001

Primary: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell…

Primary: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell…